Overview

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation

Status:
Completed

Trial end date:
2005-02-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of the monoclonal antibody rituximab plus chemotherapy with vinorelbine in treating patients with B-cell non-Hodgkin's lymphoma that has relapsed following autologous peripheral stem cell transplantation.

Phase:

Phase 2

Details

Lead Sponsor:

Jonsson Comprehensive Cancer Center

Collaborators:

Genentech, Inc.
National Cancer Institute (NCI)

Treatments:

Rituximab
Vinblastine
Vinorelbine